Report cover image

Global Multivalent Influenza Vaccines Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 206 Pages
SKU # APRC20359734

Description

Summary

According to APO Research, the global Multivalent Influenza Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Multivalent Influenza Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Multivalent Influenza Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Multivalent Influenza Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Multivalent Influenza Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Multivalent Influenza Vaccines market include CSL, KM Biologics, Viatris, AstraZeneca, Bcht Biotechnology, Sinovac, Aleph Biomedical, GSK and ADIMMUNE Corporation, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Multivalent Influenza Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Multivalent Influenza Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Multivalent Influenza Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Multivalent Influenza Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Multivalent Influenza Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Multivalent Influenza Vaccines sales, projected growth trends, production technology, application and end-user industry.

Multivalent Influenza Vaccines Segment by Company

CSL
KM Biologics
Viatris
AstraZeneca
Bcht Biotechnology
Sinovac
Aleph Biomedical
GSK
ADIMMUNE Corporation
Hualan Bio
Jiangsu GDK
Sanofi
Shanghai Institute of Biological Products
Wuhan Institute of Biological Products
Changchun Institute of Biological
Zhongyianke Biotech
Multivalent Influenza Vaccines Segment by Type

Quadrivalent Inactivated Influenza Vaccine (IIV4)
Trivalent Inactivated Influenza Vaccine (IIV3)
Trivalent Live Attenuated Vaccine (LAIV3)
Multivalent Influenza Vaccines Segment by Application

6 Months to 3 Years
Above 3 Years
Multivalent Influenza Vaccines Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Multivalent Influenza Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Multivalent Influenza Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Multivalent Influenza Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Multivalent Influenza Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multivalent Influenza Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Multivalent Influenza Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multivalent Influenza Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Multivalent Influenza Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Multivalent Influenza Vaccines industry.
Chapter 3: Detailed analysis of Multivalent Influenza Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Multivalent Influenza Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Multivalent Influenza Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

206 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Multivalent Influenza Vaccines Sales Value (2020-2031)
1.2.2 Global Multivalent Influenza Vaccines Sales Volume (2020-2031)
1.2.3 Global Multivalent Influenza Vaccines Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Multivalent Influenza Vaccines Market Dynamics
2.1 Multivalent Influenza Vaccines Industry Trends
2.2 Multivalent Influenza Vaccines Industry Drivers
2.3 Multivalent Influenza Vaccines Industry Opportunities and Challenges
2.4 Multivalent Influenza Vaccines Industry Restraints
3 Multivalent Influenza Vaccines Market by Company
3.1 Global Multivalent Influenza Vaccines Company Revenue Ranking in 2024
3.2 Global Multivalent Influenza Vaccines Revenue by Company (2020-2025)
3.3 Global Multivalent Influenza Vaccines Sales Volume by Company (2020-2025)
3.4 Global Multivalent Influenza Vaccines Average Price by Company (2020-2025)
3.5 Global Multivalent Influenza Vaccines Company Ranking (2023-2025)
3.6 Global Multivalent Influenza Vaccines Company Manufacturing Base and Headquarters
3.7 Global Multivalent Influenza Vaccines Company Product Type and Application
3.8 Global Multivalent Influenza Vaccines Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Multivalent Influenza Vaccines Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Multivalent Influenza Vaccines Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Multivalent Influenza Vaccines Market by Type
4.1 Multivalent Influenza Vaccines Type Introduction
4.1.1 Quadrivalent Inactivated Influenza Vaccine (IIV4)
4.1.2 Trivalent Inactivated Influenza Vaccine (IIV3)
4.1.3 Trivalent Live Attenuated Vaccine (LAIV3)
4.2 Global Multivalent Influenza Vaccines Sales Volume by Type
4.2.1 Global Multivalent Influenza Vaccines Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Multivalent Influenza Vaccines Sales Volume by Type (2020-2031)
4.2.3 Global Multivalent Influenza Vaccines Sales Volume Share by Type (2020-2031)
4.3 Global Multivalent Influenza Vaccines Sales Value by Type
4.3.1 Global Multivalent Influenza Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Multivalent Influenza Vaccines Sales Value by Type (2020-2031)
4.3.3 Global Multivalent Influenza Vaccines Sales Value Share by Type (2020-2031)
5 Multivalent Influenza Vaccines Market by Application
5.1 Multivalent Influenza Vaccines Application Introduction
5.1.1 6 Months to 3 Years
5.1.2 Above 3 Years
5.2 Global Multivalent Influenza Vaccines Sales Volume by Application
5.2.1 Global Multivalent Influenza Vaccines Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Multivalent Influenza Vaccines Sales Volume by Application (2020-2031)
5.2.3 Global Multivalent Influenza Vaccines Sales Volume Share by Application (2020-2031)
5.3 Global Multivalent Influenza Vaccines Sales Value by Application
5.3.1 Global Multivalent Influenza Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Multivalent Influenza Vaccines Sales Value by Application (2020-2031)
5.3.3 Global Multivalent Influenza Vaccines Sales Value Share by Application (2020-2031)
6 Multivalent Influenza Vaccines Regional Sales and Value Analysis
6.1 Global Multivalent Influenza Vaccines Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Multivalent Influenza Vaccines Sales by Region (2020-2031)
6.2.1 Global Multivalent Influenza Vaccines Sales by Region: 2020-2025
6.2.2 Global Multivalent Influenza Vaccines Sales by Region (2026-2031)
6.3 Global Multivalent Influenza Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Multivalent Influenza Vaccines Sales Value by Region (2020-2031)
6.4.1 Global Multivalent Influenza Vaccines Sales Value by Region: 2020-2025
6.4.2 Global Multivalent Influenza Vaccines Sales Value by Region (2026-2031)
6.5 Global Multivalent Influenza Vaccines Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Multivalent Influenza Vaccines Sales Value (2020-2031)
6.6.2 North America Multivalent Influenza Vaccines Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Multivalent Influenza Vaccines Sales Value (2020-2031)
6.7.2 Europe Multivalent Influenza Vaccines Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Multivalent Influenza Vaccines Sales Value (2020-2031)
6.8.2 Asia-Pacific Multivalent Influenza Vaccines Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Multivalent Influenza Vaccines Sales Value (2020-2031)
6.9.2 South America Multivalent Influenza Vaccines Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Multivalent Influenza Vaccines Sales Value (2020-2031)
6.10.2 Middle East & Africa Multivalent Influenza Vaccines Sales Value Share by Country, 2024 VS 2031
7 Multivalent Influenza Vaccines Country-level Sales and Value Analysis
7.1 Global Multivalent Influenza Vaccines Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Multivalent Influenza Vaccines Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Multivalent Influenza Vaccines Sales by Country (2020-2031)
7.3.1 Global Multivalent Influenza Vaccines Sales by Country (2020-2025)
7.3.2 Global Multivalent Influenza Vaccines Sales by Country (2026-2031)
7.4 Global Multivalent Influenza Vaccines Sales Value by Country (2020-2031)
7.4.1 Global Multivalent Influenza Vaccines Sales Value by Country (2020-2025)
7.4.2 Global Multivalent Influenza Vaccines Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.5.2 USA Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.6.2 Canada Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.8.2 Germany Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.9.2 France Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.9.3 France Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.11.2 Italy Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.12.2 Spain Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.13.2 Russia Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.16.2 China Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.16.3 China Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.17.2 Japan Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.19.2 India Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.19.3 India Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.20.2 Australia Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.24.2 Chile Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.26.2 Peru Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.28.2 Israel Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.29.2 UAE Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.31.2 Iran Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Multivalent Influenza Vaccines Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Multivalent Influenza Vaccines Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Multivalent Influenza Vaccines Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 CSL
8.1.1 CSL Comapny Information
8.1.2 CSL Business Overview
8.1.3 CSL Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.1.4 CSL Multivalent Influenza Vaccines Product Portfolio
8.1.5 CSL Recent Developments
8.2 KM Biologics
8.2.1 KM Biologics Comapny Information
8.2.2 KM Biologics Business Overview
8.2.3 KM Biologics Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.2.4 KM Biologics Multivalent Influenza Vaccines Product Portfolio
8.2.5 KM Biologics Recent Developments
8.3 Viatris
8.3.1 Viatris Comapny Information
8.3.2 Viatris Business Overview
8.3.3 Viatris Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.3.4 Viatris Multivalent Influenza Vaccines Product Portfolio
8.3.5 Viatris Recent Developments
8.4 AstraZeneca
8.4.1 AstraZeneca Comapny Information
8.4.2 AstraZeneca Business Overview
8.4.3 AstraZeneca Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.4.4 AstraZeneca Multivalent Influenza Vaccines Product Portfolio
8.4.5 AstraZeneca Recent Developments
8.5 Bcht Biotechnology
8.5.1 Bcht Biotechnology Comapny Information
8.5.2 Bcht Biotechnology Business Overview
8.5.3 Bcht Biotechnology Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.5.4 Bcht Biotechnology Multivalent Influenza Vaccines Product Portfolio
8.5.5 Bcht Biotechnology Recent Developments
8.6 Sinovac
8.6.1 Sinovac Comapny Information
8.6.2 Sinovac Business Overview
8.6.3 Sinovac Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.6.4 Sinovac Multivalent Influenza Vaccines Product Portfolio
8.6.5 Sinovac Recent Developments
8.7 Aleph Biomedical
8.7.1 Aleph Biomedical Comapny Information
8.7.2 Aleph Biomedical Business Overview
8.7.3 Aleph Biomedical Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.7.4 Aleph Biomedical Multivalent Influenza Vaccines Product Portfolio
8.7.5 Aleph Biomedical Recent Developments
8.8 GSK
8.8.1 GSK Comapny Information
8.8.2 GSK Business Overview
8.8.3 GSK Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.8.4 GSK Multivalent Influenza Vaccines Product Portfolio
8.8.5 GSK Recent Developments
8.9 ADIMMUNE Corporation
8.9.1 ADIMMUNE Corporation Comapny Information
8.9.2 ADIMMUNE Corporation Business Overview
8.9.3 ADIMMUNE Corporation Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.9.4 ADIMMUNE Corporation Multivalent Influenza Vaccines Product Portfolio
8.9.5 ADIMMUNE Corporation Recent Developments
8.10 Hualan Bio
8.10.1 Hualan Bio Comapny Information
8.10.2 Hualan Bio Business Overview
8.10.3 Hualan Bio Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.10.4 Hualan Bio Multivalent Influenza Vaccines Product Portfolio
8.10.5 Hualan Bio Recent Developments
8.11 Jiangsu GDK
8.11.1 Jiangsu GDK Comapny Information
8.11.2 Jiangsu GDK Business Overview
8.11.3 Jiangsu GDK Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.11.4 Jiangsu GDK Multivalent Influenza Vaccines Product Portfolio
8.11.5 Jiangsu GDK Recent Developments
8.12 Sanofi
8.12.1 Sanofi Comapny Information
8.12.2 Sanofi Business Overview
8.12.3 Sanofi Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.12.4 Sanofi Multivalent Influenza Vaccines Product Portfolio
8.12.5 Sanofi Recent Developments
8.13 Shanghai Institute of Biological Products
8.13.1 Shanghai Institute of Biological Products Comapny Information
8.13.2 Shanghai Institute of Biological Products Business Overview
8.13.3 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.13.4 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio
8.13.5 Shanghai Institute of Biological Products Recent Developments
8.14 Wuhan Institute of Biological Products
8.14.1 Wuhan Institute of Biological Products Comapny Information
8.14.2 Wuhan Institute of Biological Products Business Overview
8.14.3 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.14.4 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio
8.14.5 Wuhan Institute of Biological Products Recent Developments
8.15 Changchun Institute of Biological
8.15.1 Changchun Institute of Biological Comapny Information
8.15.2 Changchun Institute of Biological Business Overview
8.15.3 Changchun Institute of Biological Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.15.4 Changchun Institute of Biological Multivalent Influenza Vaccines Product Portfolio
8.15.5 Changchun Institute of Biological Recent Developments
8.16 Zhongyianke Biotech
8.16.1 Zhongyianke Biotech Comapny Information
8.16.2 Zhongyianke Biotech Business Overview
8.16.3 Zhongyianke Biotech Multivalent Influenza Vaccines Sales, Value and Gross Margin (2020-2025)
8.16.4 Zhongyianke Biotech Multivalent Influenza Vaccines Product Portfolio
8.16.5 Zhongyianke Biotech Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Multivalent Influenza Vaccines Value Chain Analysis
9.1.1 Multivalent Influenza Vaccines Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Multivalent Influenza Vaccines Sales Mode & Process
9.2 Multivalent Influenza Vaccines Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Multivalent Influenza Vaccines Distributors
9.2.3 Multivalent Influenza Vaccines Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.